What:Relypsa (NASDAQ: RLYP) , a biopharmaceutical company developing gastrointestinal medicines, saw its shares surge 58% higher at the opening bell today on the news that the Swiss-based Galenica ...

As hype around new treatments for the blood disorder hyperkalemia continues unabated after AstraZeneca's $2.7 billion buyout of ZS Pharma last year, Relypsa ($RLYP ...

It's not every day you see an FDA approval send shares lower. So what: The company has announced that its first drug, named Veltassa, has been approved for sale in the U.S. to treat hyperkalemia, or ...

SOURCE: FLICKR USER STEVE JURVETSON. What:Swirling rumors that an acquirer might step up to buy the company caused shares inRelypsa, to soar 67.6% higher today. So what: The company has been the ...

Approximately 3 million people with chronic kidney disease (CKD) and/or heart failure in the United States have hyperkalemia In clinical trials, Veltassa significantly reduced blood potassium and kept ...

Relypsa, Inc. 's RLYP lead candidate, Veltassa gained approval in the U.S. for the treatment of hyperkalemia. Shares which should have been up with the positive news were, however, down 27.2% due to ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced the completion of a Series B financing totaling $70 million.

· Veltassa will be distributed to patients via two nationally-recognized specialty pharmacies · Hospitals will receive Veltassa through a network of authorized specialty distributors · Relypsa's ...

REDWOOD CITY, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced that the United States (U.S) Food and Drug Administration (FDA) approved a ...

What: After a key competitor was acquired last Friday, shares in Relypsa climbed by 10% earlier today. So what: AstraZeneca reported on Friday that it is acquiring ZS Pharma for $2.7 billion to get ...